Engineers Gate Manager LP Atara Biotherapeutics, Inc. Transaction History

Engineers Gate Manager LP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$0.44 - $1.22 $124 - $344	-282 Reduced 0.94%	29,809 $20,000
Q4 2023 Feb 14, 2024	BUY	$0.23 - $1.74 $3,673 - $27,789	15,971 Added 113.11%	30,091 $15,000
Q3 2023 Nov 14, 2023	BUY	$1.41 - $2.31 $19,909 - $32,617	14,120 New	14,120 $20,000
Q2 2022 Aug 15, 2022	SELL	$4.69 - $9.84 $76,916 - $161,376	-16,400 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$8.44 - $16.89 $247,038 - $494,370	-29,270 Reduced 64.09%	16,400 $152,000
Q4 2021 Feb 14, 2022	BUY	$14.7 - $19.89 $671,349 - $908,376	45,670 New	45,670 $720,000
Q3 2021 Nov 15, 2021	SELL	$11.99 - $17.9 $255,746 - $381,806	-21,330 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$12.89 - $16.58 $171,694 - $220,845	-13,320 Reduced 38.44%	21,330 $332,000
Q1 2021 May 17, 2021	BUY	$14.0 - $20.72 $246,680 - $365,086	17,620 Added 103.46%	34,650 $498,000
Q4 2020 Feb 16, 2021	SELL	$12.67 - $26.23 $63,350 - $131,150	-5,000 Reduced 22.7%	17,030 $334,000
Q3 2020 Nov 16, 2020	BUY	$11.92 - $15.87 $262,597 - $349,616	22,030 New	22,030 $286,000

2.89M

Ticker ATRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 94,362,304
Market Cap $1.08B
Description
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferat...

Get notified when there are updates to the investment portfolio of Engineers Gate Manager LP, based on Form 13F filings with the SEC.

Stay updated on Engineers Gate Manager LP with notifications on news.